Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising

The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.